Nureca Limited has informed the exchange regarding the audited financial results for the quarter and financial year ended 31st March, 2026.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Ltd reported FY26 revenue of ₹1,472.10 million, up 28.4% from ₹1,146.40 million in FY25, driven by growth in home healthcare and wellness products. The company posted a marginal PAT of ₹2.97 million compared to a loss of ₹6.68 million in FY25, a turnaround aided by operating cash flow turning positive at ₹3.19 million (vs -₹188.18 million last year). Q4 FY26 saw a loss of ₹66.25 million due to a one-time fair value loss of ₹83.37 million on FVTPL investments. The company completed a share buyback of 4.75 lakh shares at ₹330/share (funded from free reserves) and approved ₹100 crore capex for medical devices manufacturing expansion at its Punjab facility. The CFO resigned for better career opportunities and will be replaced by internal promotion effective June 27, 2026. Auditors gave an unmodified (clean) opinion on the results.
Revenue growth of 28.4% is strong, but the minimal PAT margin and Q4 loss may concern investors. The ₹100 crore capex approval signals expansion plans but requires capital deployment. The CFO transition and ongoing family involvement in management are notable governance updates.